公开(公告)号：US20140057860A1

公开(公告)日：2014-02-27

申请号：US13972889

申请日：2013-08-21

Applicant: Macau University of Science and Technology

Inventor： Tao YI ,  Liang LI ,  Wai Kei Christopher LAM

IPC: A61K31/7048

CPC classification number: A61K31/7048

Abstract: The present invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and the method of preparation thereof. The aforesaid pharmaceutical composition is prepared by the following components in weight percent: 0.1%-0.3% scutellarin, 20%-25% co-surfactant, 40-50% surfactant, and 25-30% oil. The method of preparing the aforesaid pharmaceutical composition comprises the steps of: (1) dispersing scutellarin in co-surfactant and surfactant to obtain a mixture; (2) dispersing the mixture from step (1) in oil, and thermostatically and magnetically stirring the dispersion mixture under the temperature of 25° C. to 37° C., such that the components thereof are completely dissolved to obtain the pharmaceutical composition. Through the use of the selected pharmaceutical adjuvants having the ability to inhibit MRP2, the aforesaid pharmaceutical composition effectively improves absorption and bioavailability of scutellarin. The preparation of the aforesaid pharmaceutical composition is simple and convenient, and the pharmaceutical composition can be processed into a variety of dosage forms for oral administration.

Abstract translation: 本发明涉及一种治疗心血管和脑血管疾病的药物组合物及其制备方法。 上述药物组合物由以下重量百分比的组分制备：0.1％-0.3％的灯盏花乙素，20％-25％的辅助表面活性剂，40-50％的表面活性剂和25-30％的油。 制备上述药物组合物的方法包括以下步骤：（1）将灯盏花乙素分散在辅助表面活性剂和表面活性剂中以获得混合物; （2）将来自步骤（1）的混合物分散在油中，并在25℃至37℃的温度下对该分散混合物进行恒温和磁力搅拌，使其组分完全溶解，得到药物组合物。 通过使用具有抑制MRP2能力的所选择的药物佐剂，上述药物组合物有效地改善了灯盏花乙素的吸收和生物利用度。 上述药物组合物的制备简单方便，可以将药物组合物加工成多种口服给药形式。